Abstract
Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz. the protease inhibitors (boceprevir, telaprevir, and simeprevir), NS5B polymerase inhibitors (sofosbuvir) and NS5A inhibitor (ledipasvir) in combination with pegylated interferon α and ribavirin). These treatments have made a great improvement in the treatment of chronic HCV infections in recent years, but their adverse side effects, emergence of resistant mutants, high cost, and increased pill burden have limited their clinical use. Recently, with the increasing knowledge in understanding the HCV life cycle, more targets have been recognized. NS5A protein plays a critical role in assembly of infectious HCV particles and offering potential for HCV therapies. Therefore, discovery and development of novel DAAs targeting NS5A with novel mechanisms of action, are of great necessity to improve the quality of existing HCV treatments. In the present review, we discuss recent advances with NS5A inhibitors with potent anti-HCV activity, and the potential for the development of HCV NS5A inhibitors to combat HCV infections.
Keywords: Antivirals, drug design, HCV, hepatitis, inhibitors, NS5A.
Current Medicinal Chemistry
Title:The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A
Volume: 22 Issue: 15
Author(s): Diwakar Rai, Liu Wang, Xuemei Jiang, Peng Zhan, Haiyong Jia, Erik De Clercq and Xinyong Liu
Affiliation:
Keywords: Antivirals, drug design, HCV, hepatitis, inhibitors, NS5A.
Abstract: Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz. the protease inhibitors (boceprevir, telaprevir, and simeprevir), NS5B polymerase inhibitors (sofosbuvir) and NS5A inhibitor (ledipasvir) in combination with pegylated interferon α and ribavirin). These treatments have made a great improvement in the treatment of chronic HCV infections in recent years, but their adverse side effects, emergence of resistant mutants, high cost, and increased pill burden have limited their clinical use. Recently, with the increasing knowledge in understanding the HCV life cycle, more targets have been recognized. NS5A protein plays a critical role in assembly of infectious HCV particles and offering potential for HCV therapies. Therefore, discovery and development of novel DAAs targeting NS5A with novel mechanisms of action, are of great necessity to improve the quality of existing HCV treatments. In the present review, we discuss recent advances with NS5A inhibitors with potent anti-HCV activity, and the potential for the development of HCV NS5A inhibitors to combat HCV infections.
Export Options
About this article
Cite this article as:
Rai Diwakar, Wang Liu, Jiang Xuemei, Zhan Peng, Jia Haiyong, De Clercq Erik and Liu Xinyong, The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A, Current Medicinal Chemistry 2015; 22 (15) . https://dx.doi.org/10.2174/0929867322666150209150920
DOI https://dx.doi.org/10.2174/0929867322666150209150920 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myogenic Potential of Mesenchymal Stem Cells - the Case of Adhesive Fraction of Human Umbilical Cord Blood Cells
Current Stem Cell Research & Therapy Patent Selections
Recent Patents on Biotechnology The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Recent Patents and New Strategies in the Treatment of Psoriasis
Recent Patents on Anti-Infective Drug Discovery TRPM8, a Sensor for Mild Cooling in Mammalian Sensory Nerve Endings
Current Pharmaceutical Biotechnology Recent Patents on Oral Vaccine Design
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Crystallization of the N-Terminal Ankyrin Repeat Domain of the 2-5ADependent Endoribonuclease, RNase L
Protein & Peptide Letters Acknowledgements to Reviewers:
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Immunotherapy for Food Allergies in Children
Current Pharmaceutical Design Message from the Editor-in-Chief:
CNS & Neurological Disorders - Drug Targets Immune Defence Mechanisms: Comparing Upper and Lower Airways in Chronic Airway Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Management of Painful Symptoms with Duloxetine: A Review of the Efficacy in Pre-Clinical and Clinical Studies
Current Drug Therapy Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Multiple Myeloma and the Immune Microenvironment
Current Cancer Drug Targets Biomaterial Scaffolds for Mesenchymal Stem Cell Based Therapy Aimed at Tissue Engineering Application for Osteoarthritis
Recent Patents on Nanomedicine An Overall Picture of SARS Coronavirus (SARS-CoV) Genome-Encoded Major Proteins: Structures, Functions and Drug Development
Current Pharmaceutical Design Impact of Cerebral Malaria on Brain Distribution of Mefloquine
Drug Metabolism Letters A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Recent Advances in Drug Delivery: Potential and Limitations of Carbon Nanotubes
Recent Patents on Drug Delivery & Formulation Vasoconstrictor Therapy for Hepatorenal Syndrome in Liver Cirrhosis
Current Pharmaceutical Design